Takeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in big pharma. The merger was approved yesterday in a court hearing in Jersey, where Shire was ...

Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year ago, as the company shakes off the huge debts it incurred to get the deal done. Analysts ...

Insider: You mention the Shire acquisition. How important has that been for Takeda's global transformation journey? Related stories Weber: With regards to globalization, we spearheaded a ...

TOKYO: The rapidly changing global pharmaceutical landscape reached another milestone as Takeda Pharmaceutical Co completed its US$62bil acquisition of Shire Plc. Takeda’s purchase was the world ...

Takeda has reached a deal to buy Adderall drugmaker Shire for $64.3 billion. The deal comes after a handful of rejections from Shire and a short-lived potential for a bidding war between Takeda ...

Ricci has spent his entire technology career in the pharmaceutical industry, beginning at Bristol-Myers Squibb, then Johnson ...

Visit Markets Insider for constantly updated market quotes for individual stocks, ETFs, indices, commodities and currencies traded around the world. Go Now! Read next Indices Commodities ...

Takeda Pharmaceutical named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but growing ranks of women leading Japanese companies.

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.